N

Neurophth Therapeutics / 纽福斯生物科技有限公司

52 employees

Neurophth is China's first gene therapy company for ophthalmic diseases.

Basic info

Industry

biotechnology research

Sectors

Biotechnology
基因治疗
Gene Therapy
眼科疾病
Biopharmaceuticals
Life Science

Date founded

2016

Funding rounds raised

Total raised

$97M

from 12 investors over 12 rounds

N

Neurophth Therapeutics / 纽福斯生物科技有限公司 raised $97M on August 9, 2023

Investors: CMB International, Sequoia Capital China, 武汉光谷金融控股集团有限公司 and 广州金融控股集团

N

Neurophth Therapeutics / 纽福斯生物科技有限公司 raised $60M on November 23, 2021

Investors: Sequoia Capital China, Sunshine Insurance Group and CMB International

N

Neurophth Therapeutics / 纽福斯生物科技有限公司 raised $62M on February 9, 2021

Investors: Sequoia Capital China, Northern Light Venture Capital and Harvest Capital Management, Inc

N

Neurophth Therapeutics / 纽福斯生物科技有限公司 raised $18M on April 8, 2020

Investors: Sequoia Capital China

N

Neurophth Therapeutics / 纽福斯生物科技有限公司 raised undisclosed on January 1, 2018

Investors: Northern Light Venture Capital

FAQ